NSCLC: atezolizumab slows time to new brain lesions vs docetaxel

  • Lung Cancer

  • von Kelli Whitlock Burton
  • Studien – kurz & knapp
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Compared with docetaxel, second- or third-line atezolizumab prolonged time to development of new symptomatic brain lesions in patients with advanced NSCLC and a history of brain metastasis.
  • Atezolizumab also improved OS vs docetaxel in patients with no history of brain metastasis.

Why this matters

  • Up to 40% of patients with advanced NSCLC develop brain metastases.

Study design

  • 850 patients with advanced NSCLC received atezolizumab (n=425) or docetaxel (n=425) in the randomized, phase 3 OAK trial.
  • Funding: F. Hoffmann-La Roche Ltd.

Key results

  • ~14% of patients in each arm had a history of asymptomatic, treated brain metastases.
  • Atezolizumab patients with a history of brain metastasis had lower odds of developing new brain lesions by 2 years (HR, 0.38; P=.0239).
  • In patients with no brain metastases history, better median OS with atezolizumab vs docetaxel (13.2 vs 9.3 months; HR, 0.74; P=.0007).
  • In patients with a history of brain metastases, OS was better with atezolizumab vs docetaxel, although not significant (16.0 vs 11.9 months; HR, 0.74; P=.1633).
  • Fewer treatment-related adverse events (AEs), serious AEs, and treatment-related neurologic AEs with atezolizumab than with docetaxel.

Limitations

  • Variable frequency in follow-up brain scans.